What is the role of tadalafil (5 mg daily) in improving nocturia in elderly men with benign prostatic enlargement?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tadalafil 5 mg Daily for Nocturia in Elderly Men with BPE

Tadalafil 5 mg once daily provides modest but statistically significant improvement in nocturia for elderly men with benign prostatic enlargement, though the clinical benefit is small and may be less pronounced in men over 75 years old.

Evidence-Based Recommendation

The 2021 AUA guideline explicitly states that tadalafil 5 mg daily should be discussed as a treatment option for patients with LUTS/BPH irrespective of comorbid erectile dysfunction 1. The FDA-approved dosing for BPH is 5 mg once daily, taken at approximately the same time each day 2.

Efficacy for Nocturia Specifically

Magnitude of Benefit

  • Pooled analysis of four registrational trials (N=1,500) showed tadalafil reduced nocturia by -0.5 episodes versus -0.4 with placebo (treatment difference -0.2, p=0.002) 3
  • While statistically significant, this 0.2-episode difference was not considered clinically meaningful by the investigators 3
  • 47.5% of patients improved their nocturnal frequency versus 41.3% with placebo 3

Real-World Evidence

More encouraging results emerged from observational studies:

  • A Japanese multicenter study (N=31, mean age 74) demonstrated significant improvement in nocturia starting at 4 weeks and maintained through 12 weeks 4
  • Hours of undisturbed sleep (HUS) improved significantly, and nocturia-related quality of life scores showed meaningful gains 4
  • In elderly patients ≥70 years, tadalafil significantly improved both IPSS storage subscores (which include nocturia) at all time points 5

Age-Related Considerations

Critical Caveat for Elderly Patients

In men aged ≥75 years, tadalafil efficacy differs significantly from younger patients:

  • Integrated analysis of 12 studies showed a treatment-by-age interaction (p=0.034), meaning tadalafil was not statistically significantly better than placebo in the ≥75 age group 6
  • Effect sizes varied between studies, and the older cohort had more comorbidities and polypharmacy, which may have reduced efficacy 6
  • However, safety profile remained reassuring with no increased cardiovascular adverse events in aging men 6

Mechanism and Clinical Context

Tadalafil works through multiple pathways beyond simple smooth muscle relaxation:

  • Improves lower urinary tract oxygenation
  • Reduces bladder afferent nerve activity
  • Down-regulates prostate inflammation 7

Important limitation: The nocturia assessment in most trials used only IPSS Question 7 rather than voiding diaries, and did not exclude patients with nocturnal polyuria 3. This is crucial because:

Nocturia Requires Proper Evaluation First

Per the 2013 International Consultation guidelines, when nocturia is the predominant symptom, you must obtain a frequency-volume chart to differentiate 8:

  • Polyuria (24-hour output >3 liters) → lifestyle/fluid intake reduction
  • Nocturnal polyuria → fluid restriction, consider desmopressin
  • Bladder storage dysfunction → appropriate for tadalafil or other LUTS medications

Practical Algorithm

For elderly men with BPE and bothersome nocturia:

  1. Obtain frequency-volume chart to exclude polyuria/nocturnal polyuria 8
  2. If bladder-related nocturia confirmed:
    • Age <75: Tadalafil 5 mg daily is reasonable, especially if concurrent ED 1
    • Age ≥75: Consider tadalafil but set realistic expectations given reduced efficacy in this age group 6
    • Expect modest improvement (0.5-1 episode reduction) 3
  3. Monitor response at 4 weeks (earliest significant effect) 4
  4. Consider combination therapy if inadequate response (see below)

Combination Strategies

The 2021 AUA guideline specifically states: "Clinicians should not offer the combination of low-dose daily 5 mg tadalafil with alpha blockers for the treatment of LUTS/BPH as it offers no advantages in symptom improvement over either agent alone" 1.

However, if storage symptoms (including nocturia) predominate:

  • Anticholinergics or beta-3 agonists in combination with alpha blockers may be offered for moderate-to-severe storage LUTS 1
  • One study showed tadalafil plus solifenacin improved nocturia (2.7→0.7 episodes, p≤0.05) more than tadalafil alone 9

Safety Considerations

Contraindications and precautions:

  • Absolute contraindication with nitrates 2
  • Renal impairment (CrCl 30-50): Start 2.5 mg, may increase to 5 mg 2
  • Renal impairment (CrCl <30): Not recommended for daily use 2
  • No serious adverse events in elderly populations 4, 6

Bottom Line

Tadalafil 5 mg daily improves nocturia modestly in elderly men with BPE, but first rule out nocturnal polyuria with a voiding diary. The benefit is real but small (approximately 0.2-0.5 fewer episodes), with better results in men under 75 years old. The drug is most appropriate when erectile dysfunction coexists, as it addresses both conditions simultaneously. For isolated, bothersome nocturia in men over 75, alternative approaches targeting the specific etiology (fluid management, desmopressin for nocturnal polyuria, or combination therapy with antimuscarinics/beta-3 agonists) may be more effective.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.